Steba Biotech
6 articles about Steba Biotech
-
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
-
Steba Biotech Treats First Patient in Pivotal ENLIGHTED Study of Padeliporfin ImPACT in Low Grade Upper Tract Urothelial Cancer
4/20/2021
Steba Biotech, the pioneering Immune Photo Activate Cancer Treatment specialist, announces the treatment of the first patient in ENLIGHTED, its pivotal Phase 3 trial of Padeliporfin ImPACT for the treatment of Low Grade Upper Tract Urothelial Cancer.
-
BioSpace Global Roundup, March 11
3/11/2021
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Steba Biotech receives FDA Orphan Drug Designation for Padeliporfin ImPACT in Upper Tract Urothelial Cancer
3/8/2021
Steba Biotech, the IMmune Photo Activate Cancer Treatment specialist announces the U.S. Food and Drug Administration granted Orphan Drug Designation to Padeliporfin ImPACT for the treatment of adult patients with Upper Tract Urothelial Cancer.
-
Steba Biotech Announces Positive Top-Line Results From Its Latin American Phase 3 Clinical Trial Of TOOKAD In Patients With Localized Prostate Cancer And Obtains First Marketing Authorization In Mexico
2/1/2016
-
Steba Biotech Completes Its European Phase 3 Clinical Trial Of TOOKAD In Patients With Low-Risk Prostate Cancer And Submits Marketing Authorization Application To The European Medicines Agency
1/25/2016